KRAS and colorectal carcinoma: Therefore, this study was aimed to analyze the status of the two best characterized genetic and epigenetic alterations of CRC (i.e., KRAS mutation and SEPT9 promoter methylation) in a cohort of CRC patients, in order to improve our understanding of the biological aspects modulating the concordance between tissues and plasma methylation and mutation profiles.